Engineering viral vectors for acoustically targeted gene delivery.
Authors: Li HR, Harb M, Heath JE, Trippett JS, Shapiro MG, Szablowski JO
Targeted gene delivery to the brain is a critical tool for neuroscience research and has significant potential to treat human disease. However, the site-specific delivery of common gene vectors such as adeno-associated viruses (AAVs) is typically performed via invasive injections, which limit its applicable scope of research and clinical applications. Alternatively, focused ultrasound blood-brain-barrier opening (FUS-BBBO), performed noninvasively, enables the site-specific entry of AAVs into the brain from systemic circulation. However, when used in conjunction with natural AAV serotypes, this approach has limited transduction efficiency and results in substantial undesirable transduction of peripheral organs. Here, we use high throughput in vivo selection to engineer new AAV vectors specifically designed for local neuronal transduction at the site of FUS-BBBO. The resulting vectors substantially enhance ultrasound-targeted gene delivery and neuronal tropism while reducing peripheral transduction, providing a more than ten-fold improvement in targeting specificity in two tested mouse strains. In addition to enhancing the only known approach to noninvasively target gene delivery to specific brain regions, these results establish the ability of AAV vectors to be evolved for specific physical delivery mechanisms.
Introduction
Purpose
drug delivery with BBB opening
Study Objective
Engineer new AAV vectors via high-throughput in vivo selection to improve neuronal transduction at the site of focused ultrasound blood-brain barrier opening while reducing peripheral organ transduction
Animal model / Human subject
mouse (C57BL/6J, BALB/cJ, Syn1-Cre), 10-14 weeks, both sexes
Disease model
healthy
MRI or image guidance method
Yes (7-T MRI with stereotaxic targeting)
Targeted brain region(s)
Striatum
Cargo name and characteristics
AAV vectors (AAV.FUS.1-5) encoding EGFP or mCherry under CaG promoter
Route of administration
intravenous (tail vein)
Outcomes and Safety
Summary of Outcomes
Engineered AAV.FUS vectors (especially AAV.FUS.3) showed significantly improved brain transduction efficiency (up to 4.3-fold over AAV9) and reduced liver transduction (up to 6.8-fold reduction), resulting in 12.1-fold improvement in brain-to-liver targeting specificity. AAV.FUS.3 also exhibited higher neuronal tropism (69.8% vs 44.7% for AAV9) and maintained improved performance at lower dose (10⁹ vg/g) and in another mouse strain (BALB/c).
Duration of biological effect
2 weeks (expression time post-injection
Safety-related matter
Reduced liver transduction suggests lower risk of dose-limiting toxicity; no tissue damage reported.
Brain Region
Ultrasound Parameters
Ultrasound instrument
Image Guided Therapy 8-channel FUS system with 8-element annular array (diameter 25 mm, focal length 20 mm); also RK50 (FUS Instruments) for some experiments
FUS Frequency
1.5MHz
FUS Pressure
0.33MPa
FUS Mode
pulsed
Pulse duration
10ms (calculated)
Duration of a single FUS session
120s
Focal Characteristics
natural focal point 20 mm, diameter 25 mm
Treatment frequency
single session
We are open to feedback. If you see a mistake or have a suggestion, please contact us.
← Back to Search